Int J Clin Oncol. 2022 Mar 8. doi: 10.1007/s10147-022-02118-8. Online ahead of print.
NO ABSTRACT
PMID:35257278 | DOI:10.1007/s10147-022-02118-8
Categories
Correction to: Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B)
